Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
The company showcased three core programs developed through this platform
Commercial production is expected to begin soon
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
The audit has been concluded with no major observations
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
Subscribe To Our Newsletter & Stay Updated
